Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Alzamend Neuro Receives FDA “Study May Proceed” Notification for Phase IIA Clinical Trial of AL001
Brief: Alzamend Neuro Regains Compliance With Nasdaq’S Minimum Bid Price Requirement
Brief: Alzamend Neuro Submits IND Application For A Phase IIA Clinical Trial
Brief: Alzamend Neuro Announces Reverse Stock Split
Brief: Alzamend Neuro Submits IND Application For A Phase III Clinical Trial In Major Depressive Disorder Patients
Brief: Alzamend Neuro Receives FDA 'Study May Proceed' Notification For A Phase IIa Clinical Trial Of Al001, In Bipolar Disorder Patients
Brief: Alzamend Neuro Inc Received Notice Of Delisting From Nasdaq
Brief: Alzamend Neuro Granted Extension By Nasdaq Panel To Regain Compliance With The Minimum Bid Price Continued Listing Requirement
U.S. RESEARCH ROUNDUP-Planet Fitness, PTC Therapeutics, Skechers USA
Alzamend Neuro Inc reports results for the quarter ended in July - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Alzamend Neuro Says On Sept 8, Entered At-The-Market Issuance Sales Agreement To Sell Common Shares Of Up To About $9.8 Million
Brief: Alzamend Neuro Submits Ind Application For Phase Iia Clinical Trial Of Al001
Brief: Alzamend Neuro - On August 1, Co Was Notified By Nasdaq It Had Not Regained Compliance With Listing Rule
Brief: Alzamend Neuro Inc Files For Mixed Shelf Of Upto $25 Million
Brief: Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results For AL001
Brief: Ault Alliance Announces Alzamend Neuro Has Initiated Phase I/Iia Trial For Its Immunotherapy Vaccine (Alzn002)
Alzamend Neuro rises on initiating early-stage trials for Alzheimer’s vaccine